You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
ODB - General Benefit
    prednisone
New Drug Funding Program
    Polatuzumab Vedotin with Rituximab (Biosimilar IV and Rituximab SC) – In Combination with Chemotherapy for Previously Untreated LBCL
New Drug Funding Program
    Polatuzumab Vedotin with Rituximab (Biosimilar IV and Rituximab SC) – In Combination with Chemotherapy for Previously Untreated LBCL
New Drug Funding Program
    Polatuzumab Vedotin with Rituximab (Biosimilar IV and Rituximab SC) – In Combination with Chemotherapy for Previously Untreated LBCL
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
prednisone,
riTUXimab,
polatuzumab vedotin,
DOXOrubicin,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2026